

Special Issue

Anticancer Prodrug

Message from the Guest Editor

I would like to invite you to contribute an article to upcoming special issue of *Pharmaceutics* focusing on the development and clinical potential of anticancer prodrugs. The general scope of this special issue is outlined below. Anticancer prodrugs can broadly be defined as nontoxic agents selectively activated to chemotherapeutic drugs in cancer cells, tumors or the tumor microenvironment. Anticancer prodrugs can also serve as adjuvants to enhance or beneficially affect another cancer therapy, e.g., radiation therapy. As a branch of precision oncology, the clinical application of anticancer prodrugs holds the promise of individualized treatment with the maximum therapeutic response with minimum side-effects. The application of “omics” technologies, such as genomics and proteomics, to characterize tumors is rapidly advancing the discovery of novel cancer biomarkers. : *Keywords*

- anticancer
- prodrugs
- chemotherapy
- personalized medicine
- tumors
- oxidative stress
- hypoxia
- proteomics
- genomics

Guest Editor

Prof. Dr. William L. Stone

Department of Pediatrics, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, TN 37614, USA

Deadline for manuscript submissions

closed (30 April 2019)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/21202

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).